EC approves GSK/Theravance's Relvar Ellipta for both COPD and asthma
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorization for Relvar Ellipta, the asthma and chronic obstructive pulmonary disease (COPD) treatment developed by GlaxoSmithKline and Theravance.